A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models

B cell lymphoma (BCL) is the most frequently diagnosed type of non-Hodgkin lymphoma (NHL), and accounts for about 4% of all cancers in the USA. Kinases spleen tyrosine kinase (Syk), Src, and Janus kinase 2 (JAK2) have been thought as potential targets for the treatment of BCL. We have recently devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Nannan, Zhang, Guo, Liu, Ning, Lin, Wanting, Ji, Sen, Zheng, Mingwu, Chen, Kai, Liang, Xiao, Li, Guobo, Ma, Yu, Zhu, Jun, Niu, Ting, Li, Lin-Li, Li, Jiong, Wei, Yu-Quan, Yang, Sheng-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762338/
https://www.ncbi.nlm.nih.gov/pubmed/29340070
http://dx.doi.org/10.18632/oncotarget.22847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762338/
https://www.ncbi.nlm.nih.gov/pubmed/29340070
http://dx.doi.org/10.18632/oncotarget.22847

Ejemplares similares